209 related articles for article (PubMed ID: 11978778)
1. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
Naves R; Lennon AM; Barbieri G; Reyes L; Puga G; Salas L; Deffrennes V; Rosemblatt M; Fellous M; Charron D; Alcaïde-Loridan C; Bono MR
Int Immunol; 2002 May; 14(5):481-91. PubMed ID: 11978778
[TBL] [Abstract][Full Text] [Related]
2. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
3. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
4. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
[TBL] [Abstract][Full Text] [Related]
5. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
6. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
7. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression.
Murphy SP; Tomasi TB
Mol Reprod Dev; 1998 Sep; 51(1):1-12. PubMed ID: 9712312
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.
Steimle V; Siegrist CA; Mottet A; Lisowska-Grospierre B; Mach B
Science; 1994 Jul; 265(5168):106-9. PubMed ID: 8016643
[TBL] [Abstract][Full Text] [Related]
9. The RAG cell line defines a new complementation group of MHC class II deficiency.
Lennon A; Ottone C; Peijnenburg A; Hamon-Benais C; Colland F; Gobin S; van den Elsen P; Fellous M; Bono R; Alcaïde-Loridan C
Immunogenetics; 1996; 43(6):352-9. PubMed ID: 8606055
[TBL] [Abstract][Full Text] [Related]
10. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression.
Dong Y; Tang L; Letterio JJ; Benveniste EN
J Immunol; 2001 Jul; 167(1):311-9. PubMed ID: 11418665
[TBL] [Abstract][Full Text] [Related]
11. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
12. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
13. Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases.
Yau AC; Piehl F; Olsson T; Holmdahl R
Immunology; 2017 Apr; 150(4):408-417. PubMed ID: 27861821
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.
Lu Y; Tschickardt ME; Schmidt BJ; Blanck G
Immunol Cell Biol; 1997 Aug; 75(4):325-32. PubMed ID: 9315472
[TBL] [Abstract][Full Text] [Related]
16. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.
Piskurich JF; Gilbert CA; Ashley BD; Zhao M; Chen H; Wu J; Bolick SC; Wright KL
Mol Immunol; 2006 Feb; 43(6):519-28. PubMed ID: 15950283
[TBL] [Abstract][Full Text] [Related]
17. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.
Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA
Immunity; 1996 Feb; 4(2):167-78. PubMed ID: 8624807
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
19. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
[TBL] [Abstract][Full Text] [Related]
20. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
